[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421623":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":64,"collaborators":39,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":39,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":39,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":47,"whyStopped":39,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: DC-Beads loading with Chemodrug\u002FIL2\u002FPD1\u002FCTLA4 antibodies","EXPERIMENTAL","Intra-tumor injection of above drugs for patients with previous treatment with PDL1 antibody and relapsed.",[13],"Drug: Injection of drug-eluting microspheres with multiple drugs into solid tumors",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2: DC-Beads loading with Chemodrug\u002FIL2\u002FPDL1\u002FCTLA4 antibodies","Intra-tumor injection of above drugs for patients with previous treatment with PD1 antibody and relapsed.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3: DC-Beads loading with Chemodrug\u002FIL2\u002FPD1\u002FPDL1\u002FCTLA4 antibodies","Intra-tumor injection of above drugs for patients with previous heavily treated with PD1\u002FPDL1\u002FCTLA4 antibodies and relapsed.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Injection of drug-eluting microspheres with multiple drugs into solid tumors","Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor",[9,15,19],[29],"Checkpoint inhibitor (CPI) such as Keytruda plus chemodrug",[31],{"name":32,"affiliation":5,"role":33},"Zhenfeng Zhang, MD, PhD","PRINCIPAL_INVESTIGATOR",[35,41],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Bingjia He, MD","CONTACT","+862039195965",null,"464677938@qq.com",{"name":32,"role":37,"phone":42,"phoneExt":39,"email":43},"+862039195966","zhangzhf@gzhmu.edu.cn",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The Second Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510260","China","CN",{"type":54,"coordinates":55},"Point",[56,57],113.25,23.11667,{"lat":57,"lon":56},[60,63],{"name":61,"role":37,"phone":62,"phoneExt":39,"email":40},"BINGJIA HE, MD","13560199303",{"name":32,"role":37,"phone":42,"phoneExt":39,"email":43},{"type":65,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100421623","phase-2-intra-tumor-injection-of-drug-eluting-microspheres-with-multiple-drugs-100421623",false,"NCT04770207","Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and\u002For IL2 for Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n* Solid advanced malignant tumors\n* Age between18 and 99 years\n* Life expectancy is greater than three months\n\nExclusion Criteria:\n\n* Benign tumor\n* Life expectancy is less than three months\n* Serious medical comorbidity\n* Others","ALL","18 Years","99 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and\u002For protein drugs into advanced solid tumors.",[84,85],"Hepatocellular Carcinoma","Solid Tumor, Adult",[87,88,89,90,91,92],"Hepatocellular Carcinoma; Lung Cancer; Solid Tumors","Drug-eluting Beads","IL2; Kytruda; Opdivo; Imfinza; Atezolizumab; Ipilimumab;","Treprizolizumab; Tirelizumab; Carellizumab; Sintilimab;","Sugemalimab；Adebrelimab；Envafolimab；Cadonilimab；","Bevacizumab; Ramucirumab","2024-08-19",{"date":95,"type":96},"2024-08-21","ACTUAL",{"date":98,"type":96},"2020-11-01",{"date":100,"type":78},"2035-11-01",{"name":5,"class":6},1]